Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Rhea-AI Summary
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on Cellectis’ investor website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CLLS
On the day this news was published, CLLS declined 3.83%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $253.19M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CLLS gained 3.77% as peers showed mixed moves: ENGN +5.23%, GLUE +4.02%, KRRO +8.22%, ABEO +2.9%, while FDMT slipped 0.59%, pointing to stock-specific rather than synchronized sector trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 12 | Clinical data update | Positive | -0.5% | Announced upcoming lasme‑cel and eti‑cel clinical data at EHA 2026. |
| May 11 | Quarterly earnings | Neutral | -0.5% | Reported first quarter 2026 financial results to investors. |
| May 06 | Capital structure update | Neutral | -2.3% | Published monthly statement of share capital and voting rights. |
| May 04 | Earnings date notice | Neutral | +1.6% | Announced timing for release of Q1 2026 financial results. |
| Apr 27 | R&D platform update | Positive | -0.3% | Presented TALE-based epigenetic editing platform data at ASGCT meeting. |
Recent positive R&D and clinical updates often saw flat to negative next-day reactions, while administrative or scheduling news showed small, mixed moves.
Over the last few months, Cellectis issued multiple updates on its CAR-T programs and corporate events. On Apr 27, 2026, it highlighted new epigenetic editing data, followed by earnings scheduling on May 4 and Q1 results on May 11. Clinical data presentations for lasme‑cel and eti‑cel were announced on May 12, while regular share-capital disclosures continued. Today’s AGM announcement fits into this pattern of steady corporate and scientific communication rather than a new financial or clinical inflection point.
Regulatory & Risk Context
The company has an effective F-3 shelf registration dated 2025-07-02, expiring on 2028-07-02, with no recorded usage to date in the provided context.
Market Pulse Summary
This announcement schedules Cellectis’ annual general meeting for June 25, 2026 at 2:30 p.m. CET in Paris, a standard corporate-governance event rather than a new financial or clinical milestone. It follows recent updates on CAR‑T programs, financial results, and epigenetic editing research. Investors may focus more on upcoming clinical readouts and financial disclosures outlined in recent filings, while the effective F‑3 shelf and ongoing R&D spending frame the medium-term funding and execution backdrop.
Key Terms
gene-editing medical
AI-generated analysis. Not financial advice.
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
